Evolent Health Inc Class A (EVH)

Evolent Health's stock price has experienced a significant decline over the past year, but has shown considerable volatility over the past six months. Key events impacting the stock include Q3 2025 earnings where revenue beat estimates but EPS missed expectations, the sale of its value-based primary care business to Privia Health Group, Inc., and an offering of convertible senior notes to repurchase existing notes and Class A Common Stock. Several analysts have maintained 'Buy' or 'Outperform' ratings, though some have lowered price targets. A board member retired and a new independent director was appointed. The company announced new revenue agreements, including a partnership with a large regional Blues plan for oncology and an expansion of oncology and cardiology solutions to a new Midwestern state.

Evolent Health's annualized revenue growth over the last two years has been above its five-year trend, suggesting strong and recently accelerated demand, driven by rising medical costs. However, analysts expect revenue to decline over the next 12 months, and the company's revenue guidance reflects some anticipated declines. Despite near-term challenges, Evolent Health anticipates exceeding $2.5 billion in revenues by 2026, driven by organic expansion and efficiency gains through AI, underscoring long-term growth opportunities.

Evolent Health, Inc. is a healthcare company providing technology-enabled services and solutions to health plans and providers, focusing on value-based care and population health management. The company operates within the Healthcare sector, specifically in the Health Information Services industry, helping healthcare organizations transition to value-based payment models. Its services include specialty care management for complex conditions, total cost of care management, administrative services with an integrated platform, Identifi for data analysis and care workflow management, Machinify Auth for AI-enhanced clinical reviews, and the True Health segment offering a physician-led health plan.

Evolent Health, Inc. primarily serves a national base of leading payers and providers across the United States, helping organizations deliver high-quality, affordable care. The company's headquarters are located in Arlington, Virginia.

Evolent Health has positioned itself as a trusted partner for health plans and providers, focusing on improving health outcomes through value-based specialty care solutions and has been recognized as a top place to work in healthcare nationally. In July 2023, the company rebranded to reflect its focus on integrated, clinically focused care across specialties. However, the company's reputation has also been affected by financial challenges and stock performance, with shares declining significantly. Despite these financial hurdles, analysts generally maintain a positive outlook.

Evolent Health, Inc. is largely an institutional stock, with institutions owning approximately 81.9% of the company. Major institutional owners include Cadian Capital Management, Lp, Vanguard Group Inc, and BlackRock, Inc. Individual insiders hold a smaller portion, approximately 1.4% of the shares, and insider buying has been observed in the past three months.